Zydus introduces cancer treatment IBYRA in India, making advanced therapy accessible
In a groundbreaking development for cancer treatment in India, Zydus Lifesciences has launched Olaparib under the brand name IBYRA, a pioneering PARP inhibitor designed to ... Read More
Kinnate Biopharma agrees to merger with XOMA, boosting shareholder value and advancing cancer research
Kinnate Biopharma Inc. (Nasdaq: KNTE), a leading clinical-stage precision oncology company, has announced a definitive merger agreement with XOMA Corporation, setting the stage for a ... Read More
Buckingham Palace confirms King Charles’s cancer diagnosis and treatment plan
In a sobering announcement from Buckingham Palace on Monday, it was revealed that King Charles III has been diagnosed with an unspecified type of cancer, ... Read More
Gilead Sciences invests $320m in Arcus Biosciences to accelerate cancer treatment innovations
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) have announced a significant amendment to their collaboration agreement, accompanied by a substantial $320 ... Read More
Bristol Myers Squibb’s subcutaneous nivolumab shows promise in Phase 3 RCC trial
Bristol Myers Squibb (NYSE: BMY) has announced results from its Phase 3 CheckMate -67T trial, which could revolutionize treatment for patients with advanced or metastatic ... Read More
Debiopharm, ThinkingNodeLife.ai join forces to advance AI-driven cancer drug development
Debiopharm, an independent biopharmaceutical company based in Switzerland, has forged a collaborative partnership with USA's ThinkingNodeLife.ai (TNL), a pioneer in AI Digital Cells Lab, to ... Read More
Zydus Lifesciences gains FDA approval for Cyclophosphamide Capsules
Zydus Lifesciences Limited, a leading pharmaceutical company, has achieved a significant milestone by receiving final approval from the United States Food and Drug Administration (USFDA) ... Read More
FDA approves Ryzneuta by Evive Biotech for reducing febrile neutropenia in cancer patients
Evive Biotech, a global biopharmaceutical company and a subsidiary of Yifan Pharmaceutical Co. Ltd., along with New Jersey-based Acrotech Biopharma, a wholly-owned subsidiary of Aurobindo ... Read More
ValiRx and StingRay Bio collaborate on preclinical cancer therapeutics research
ValiRx Plc (AIM: VAL), a pioneering life science company, has entered into a strategic agreement with StingRay Bio Limited to evaluate a series of drug ... Read More
Crown Bioscience launches OrganoidXplore: A game-changer for preclinical oncology research
Leading global contract research organization, Crown Bioscience, has unveiled OrganoidXplore, a trailblazing service offering in the domain of preclinical oncology research. This state-of-the-art platform promises ... Read More